The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Open accessAbstract
BACKGROUND: Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. METHODS: We conducted two randomized, double-blind, controlled trials involving otherwise healthy outpatients with acute uncomplicated influenza. After a dose-ranging (10 to 40 mg) placebo-controlled trial, we undertook a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir (40 or 80 mg) in patients 12 to 64 years of age during the 2016-2017 season. The dose of oseltamivir was 75 mg twice daily for 5 days. The primary efficacy end point was the time to alleviation of influenza symptoms in the intention-to-treat infected population. RESULTS: In the phase 2 trial, the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours shorter in the baloxavir groups than in the placebo group (P<0.05). In the phase 3 trial, the intention-to-treat infected population included 1064 patients; 84.8 to 88.1% of patients in each group had influenza A(H3N2) infection. The median time to alleviation of symptoms was 53.7 hours (95% confidence interval [CI], 49.5 to 58.5) with baloxavir, as compared with 80.2 hours (95% CI, 72.6 to 87.1) with placebo (P<0.001). The time to alleviation of symptoms was similar with baloxavir and oseltamivir. Baloxavir was associated with greater reductions in viral load 1 day after initiation of the regimen than placebo or oseltamivir. Adverse events were reported in 20.7% of baloxavir recipients, 24.6% of placebo recipients, and 24.8% of oseltamivir recipients. The emergence of polymerase acidic protein variants with I38T/M/F substitutions conferring reduced susceptibility to baloxavir occurred in 2.2% and 9.7% of baloxavir recipients in the phase 2 trial and phase 3 trial, respectively. CONCLUSIONS: Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza. Evidence for the development of decreased susceptibility to baloxavir after treatment was also observed. (Funded by Shionogi; JapicCTI number, 153090, and CAPSTONE-1 ClinicalTrials.gov number, NCT02954354 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J. D., Chau, T. N. B., Hoang, D. M., Van Vinh Chau, N., Khanh, T. H., Dong, V. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1477 · Cited by 1,858
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Self-citationEfficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized with Influenza
Lee, N., Chan, P. K. S., Hui, D. S. C., Rainer, T. H., Wong, E., Choi, K., Lui, G. C. Y., Wong, B. C. K., Wong, R. Y. K., Lam, W., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600383 · Cited by 526
Self-citationCrystal structure of an avian influenza polymerase PAN reveals an endonuclease active site
Yuan, P., Bartlam, M., Lou, Z., Chen, S., Zhou, J., He, X., Lv, Z., Ge, R., Li, X., Deng, T., et al. (2009) · Nature · doi:10.1038/nature07720 · Cited by 497
Structure of influenza A polymerase bound to the viral RNA promoter
Pflug, A., Guilligay, D., Reich, S., & Cusack, S. (2014) · Nature · doi:10.1038/nature14008 · Cited by 481
Structural insight into cap-snatching and RNA synthesis by influenza polymerase
Reich, S., Guilligay, D., Pflug, A., Malet, H., Berger, I., Crépin, T., Hart, D., Lunardi, T., Nanao, M., Ruigrok, R. W. H., et al. (2014) · Nature · doi:10.1038/nature14009 · Cited by 465
Early administration of oral oseltamivir increases the benefits of influenza treatment
Aoki, F. Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg007 · Cited by 424
Hu, Y., Lu, S., Song, Z., Wang, W., Hao, P., Li, J., Zhang, X., Yen, H.-L., Shi, B., Li, T., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61125-3 · Cited by 355
Memoli, M. J., Athota, R., Reed, S., Czajkowski, L., Bristol, T., Proudfoot, K., Hagey, R., Voell, J., Fiorentino, C., Ademposi, A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit725 · Cited by 274
Hurt, A. C., Chotpitayasunondh, T., Cox, N. J., Daniels, R., Fry, A. M., Gubareva, L. V., Hayden, F. G., Hui, D. S., Hungnes, O., Lackenby, A., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70318-8 · Cited by 228
Self-citationClark, M. P., Ledeboer, M. W., Davies, I., Byrn, R. A., Jones, S. M., Perola, E., Tsai, A., Jacobs, M., Nti-Addae, K., Bandarage, U. K., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5007275 · Cited by 219
Clinical Implications of Antiviral Resistance in Influenza
Li, T., Chan, M., & Lee, N. (2015) · Viruses · doi:10.3390/v7092850 · Cited by 175
Self-citationStevaert, A., & Naesens, L. (2016) · Medicinal Research Reviews · doi:10.1002/med.21401 · Cited by 170
Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus Infection
Kohno, S., Kida, H., Mizuguchi, M., & Shimada, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-10 · Cited by 157
South East Asia Infectious Disease Clinical Research Network (2013) · BMJ · doi:10.1136/bmj.f3039 · Cited by 141
Leekha, S., Zitterkopf, N. L., Espy, M. J., Smith, T. F. A., Thompson, R. L., & Sampathkumar, P. (2007) · Infection Control and Hospital Epidemiology · doi:10.1086/520101 · Cited by 138
Choi, S., Boudreault, A. A., Xie, H., Englund, J. A., Corey, L., & Boeckh, M. (2011) · Blood · doi:10.1182/blood-2010-11-319186 · Cited by 136
Lee, N. L. S., Chan, P. K. S., Wong, C. K., Wong, K.-T., Choi, K., Joynt, G. M., Lam, P., Chan, M. C. W., Wong, B. C. K., Lui, G. C.-Y., et al. (2010) · Antiviral Therapy · doi:10.3851/imp1722 · Cited by 123
Self-citationEvaluation of Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients
de Jong, M. D., Ison, M. G., Monto, A. S., Metev, H., Clark, C. L., O’Neil, B. J., Elder, J., McCullough, A. J., Collis, P., & Sheridan, W. P. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu632 · Cited by 117
Marty, F. M., Puigserver, J. V., Clark, C. L., Gupta, S. K., Merino, E., Garot, D., Chapman, M. J., Jacobs, F., Rodríguez-Noriega, E., Husa, P., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30435-0 · Cited by 104
Stevaert, A., Dallocchio, R. N., Dessì, A., Pala, N., Rogolino, D., Sechi, M., & Naesens, L. M. J. (2013) · Journal of Virology · doi:10.1128/jvi.00832-13 · Cited by 81
Fielding, J., Kelly, H. A., Mercer, G. N., & Glass, K. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12216 · Cited by 70
Reddy, K. P., Bajwa, E. K., Parker, R. A., Onderdonk, A. B., & Walensky, R. P. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw023 · Cited by 14
Cited by
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Self-citationFavipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573
Uyeki, T. M., Hui, D. S., Zambon, M., Wentworth, D. E., & Monto, A. S. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00982-5 · Cited by 560
Angus, D. C., Berry, S., Lewis, R. J., Al-Beidh, F., Arabi, Y., van Bentum-Puijk, W., Bhimani, Z., Bonten, M., Broglio, K., Brunkhorst, F., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-192sd · Cited by 446
Self-citation
Metadata
- Authors
- Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., Kawaguchi, K., Shishido, T., Arai, M., Tsuchiya, K., Uehara, T., & Watanabe, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-09-06
- Volume
- 379
- Issue
- 10
- Pages
- 913-923
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892275685
- Cited by
- 925
- References
- 24
- FWCI
- 72.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.